Gain Therapeutics (GANX) Capital Expenditures (2020 - 2026)

Gain Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at -$10766.0 in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 1165.1% year-over-year to -$10766.0 in Q2 2026; TTM through Jun 2026 was -$10927.0, a 1213.34% decrease from a year earlier, with the FY2025 full-year figure at -$2852.0, down 112.68% from the prior year.
• Capital Expenditures was -$10766.0 for Q2 2026 at Gain Therapeutics, down from $913.0 in the prior quarter.
• The five-year high for Capital Expenditures was $271304.0 in Q4 2022, with the low at -$204727.0 in Q3 2022.
• Average Capital Expenditures over 5 years is $8005.5, with a median of $629.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Capital Expenditures jumped 1678.95% in 2024, then slumped 1165.1% in 2026.
• Over 5 years, Capital Expenditures stood at $271304.0 in 2022, then sank by 99.99% to $19.0 in 2023, then surged by 1678.95% to $338.0 in 2024, then plunged by 257.69% to -$533.0 in 2025, then plunged by 1919.89% to -$10766.0 in 2026.
• The last three Capital Expenditures figures came in at -$10766.0 (Q2 2026), $913.0 (Q1 2026), and -$533.0 (Q4 2025), per Business Quant data.